Literature DB >> 12065793

Unique features of the mode of action of ET-743.

Maurizio D'Incalci1, Eugenio Erba, Giovanna Damia, Emanuela Galliera, Laura Carrassa, Sergio Marchini, Roberto Mantovani, Gianluca Tognon, Robert Fruscio, José Jimeno, Glynn T Faircloth.   

Abstract

This paper describes the current knowledge of the primary mode of action of a natural product, ecteinascidin 743 (ET-743), derived from the marine tunicate Ecteinascidia turbinata. ET-743 was initially selected for preclinical development because of its potent antitumor activity observed against several human solid tumor types. In vitro, the drug is cytotoxic in the nanomolar range, and in the case of some very sensitive cell lines, in the picomolar range. The large potency differences observed among several solid tumor types indicate that this compound possesses some tumor selectivity, but the molecular basis of these differential effects remains to be elucidated. The present studies were undertaken to evaluate the mechanism of action of ET-743 in this context. The available information on ET-743 binding to DNA and its effects on transcriptional regulation point to a unique behavior of this drug, as it independently affects specific gene transcription in a promoter-dependent way. In addition, ET-743 shows a peculiar pattern of selectivity in cells with different defects in their DNA-repair pathways. These results highlight a unique property of ET-743, possibly explaining why it possesses antitumor activity against tumors that are refractory to standard anticancer drugs, all of which certainly act by mechanisms that are different from that of ET-743.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065793     DOI: 10.1634/theoncologist.7-3-210

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

1.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

2.  In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

3.  Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Authors:  Emiliano Calvo; Analia Azaro; Jordi Rodon; Luc Dirix; Manon Huizing; Francis Mark Senecal; Patricia LoRusso; Lorrin Yee; Italo Poggesi; Jan de Jong; Spyros Triantos; Youn C Park; Roland E Knoblauch; Trilok V Parekh; George D Demetri; Margaret von Mehren
Journal:  Invest New Drugs       Date:  2017-11-27       Impact factor: 3.850

4.  Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Authors:  Luis Paz-Ares; Antonio López-Pousa; Andrés Poveda; Carmen Balañá; Eva Ciruelos; Joaquim Bellmunt; Javier García del Muro; Mariano Provencio; Antonio Casado; Fernando Rivera-Herrero; Miguel Angel Izquierdo; Antonio Nieto; Adnan Tanović; Hernán Cortes-Funes; José María Buesa
Journal:  Invest New Drugs       Date:  2010-10-20       Impact factor: 3.850

5.  Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Authors:  Gregory J Aune; Kazutaka Takagi; Olivier Sordet; Josée Guirouilh-Barbat; Smitha Antony; Vilhelm A Bohr; Yves Pommier
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 6.  Inflammation and cancer: advances and new agents.

Authors:  Shanthini M Crusz; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

7.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Authors:  S B Kaye; N Colombo; B J Monk; S Tjulandin; B Kong; M Roy; S Chan; E Filipczyk-Cisarz; H Hagberg; I Vergote; C Lebedinsky; T Parekh; P Santabárbara; Y C Park; A Nieto; A Poveda
Journal:  Ann Oncol       Date:  2010-07-19       Impact factor: 32.976

8.  A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.

Authors:  L Zelek; A Yovine; E Brain; F Turpin; A Taamma; M Riofrio; M Spielmann; J Jimeno; J L Misset
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

9.  DNA and the chromosome - varied targets for chemotherapy.

Authors:  Stephanie M Nelson; Lynnette R Ferguson; William A Denny
Journal:  Cell Chromosome       Date:  2004-05-24

10.  In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.

Authors:  C Simoens; A E C Korst; C M J De Pooter; H A J Lambrechts; G G O Pattyn; G T Faircloth; F Lardon; J B Vermorken
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.